Genetically modified human myoblasts with eNOS may improve regenerative ability of myogenic stem cells to infarcted heart.

BACKGROUND Modern therapies of post infarcted heart failure are focused on perfusion improvement of the injured myocardium. This effect can be achieved by, among other means, implanting stem cells which could be genetically modified with factors inducing the formation of new blood vessels in the post infarction scar area. Combined stem cell and gene therapy seems to be a promising strategy to heal an impaired myocardium. The creation of new blood vessels can be indirectly stimulated via factors inducing vascular endothelial growth factor synthesis, for example endothelial nitric oxide synthase (eNOS). The product of this enzyme, nitric oxide, is a molecule that can influence numerous physiological activities; it can contribute to vasodilation, stimulation of endothelial cell growth, prevention of platelet aggregation and leukocyte adhesion to the endothelium. AIM To verify the pro-angiogenic and regenerative potential of human primary myoblasts and murine myoblast cell line C2C12 transiently transfected with eNOS gene. METHODS Stem cells (either human or murine) were maintained in standard in vitro conditions. Next, both types of myoblasts were modified using electroporation and lipofection (human and murine cells), respectively. The efficacy of the transfection method was evaluated using flow cytometry. The concentration of eNOS protein was measured by ELISA immunoassay. The biological properties of modified cells were assessed using an MTT proliferation test and DAPI cell cycle analysis. To verify the influence of oxidative stress on myoblasts, cytometric tests using Annexin V and propidium iodide were applied. To check possible alterations in myogenic gene expression of stem cells transduced by genetic modification, the myogenic regulatory factors were evaluated by real-time PCR. The function of genetic modification was confirmed by a HUVEC capillary sprouting test using myoblasts supernatants. RESULTS Electroporation turned out to be an efficient transfection method. High amounts of secreted protein were obtained (in the range 2,000 pg/mL) in both cell types studied. Moreover, the functionality of gene overexpression product was confirmed in capillary development assay. Human myoblasts did not exhibit any changes in cell cycle; however, eNOS transfected murine myoblasts revealed a statistically significant reduction in cell cycle ratio compared to controls (p < 0.001). In the case of myogenic gene expression, a decrease in Myogenin level was only detected in the human transfected myoblast population (p < 0.05). CONCLUSIONS The results of our study may suggest that transplantation of myoblasts overexpressing eNOS could be promising for cell therapy in regenerating the post infarction heart.

[1]  P. Menasché.  Cardiac cell therapy: lessons from clinical trials. , 2011, Journal of molecular and cellular cardiology.

[2]  P. Menasché.  Skeletal myoblasts and cardiac repair. , 2008, Journal of molecular and cellular cardiology.

[3]  N. Maulik,et al.  Growth factors and cell therapy in myocardial regeneration. , 2008, Journal of molecular and cellular cardiology.

[4]  E. Olson,et al.  Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. , 2007, The Journal of clinical investigation.

[5]  P. Boekstegers,et al.  Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. , 2007, Journal of the American College of Cardiology.

[6]  K. Tomczak,et al.  Myoblast preparation for transplantation into injured myocardium , 2006 .

[7]  A. Muotri,et al.  Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. , 2006, International journal of cardiology.

[8]  C. Murry,et al.  Regenerating the heart , 2005, Nature Biotechnology.

[9]  D. Fiszer,et al.  Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. , 2004, American heart journal.

[10]  P. Cattini,et al.  Cell transplantation for treatment of acute myocardial infarction: unique capacity for repair by skeletal muscle satellite cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[11]  A. Mangi,et al.  Enhanced Inhibition of Neointimal Hyperplasia by Genetically Engineered Endothelial Progenitor Cells , 2004, Circulation.

[12]  F. Sellke,et al.  Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia , 2003, Gene Therapy.

[13]  K. Kamiński,et al.  Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury. , 2002, International journal of cardiology.

[14]  J. Cooke,et al.  Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. , 2001, Cardiovascular research.

[15]  C. Bader,et al.  Efficient non-viral DNA-mediated gene transfer to human primary myoblasts using electroporation , 2001, Neuromuscular Disorders.

[16]  M. Rudnicki,et al.  A new look at the origin, function, and "stem-cell" status of muscle satellite cells. , 2000, Developmental biology.

[17]  A M Zeiher,et al.  Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  H. Granger,et al.  VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[19]  H. Granger,et al.  Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. , 1997, Circulation research.

[20]  M. Rudnicki,et al.  Determination versus differentiation and the MyoD family of transcription factors. , 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[21]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[22]  B. Lévy,et al.  Endothelial nitric oxide synthase overexpression restores the efficiency of bone marrow mononuclear cell-based therapy. , 2011, The American journal of pathology.

[23]  Lan Huang,et al.  Transplantation of endothelial progenitor cells overexpressing endothelial nitric oxide synthase enhances inhibition of neointimal hyperplasia and restores endothelium-dependent vasodilatation. , 2011, Microvascular research.

[24]  C. Emerson,et al.  Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. , 2002, Annual review of cell and developmental biology.